$ONCT Only small-cap in clinic with ROR1 antibody. πŸ‘€ +$100M cash + 6 data updates 1H 21 ROR1 a very hot target πŸ”₯ Nov 2020; Velosbio (spun-out of $ONCT three years ago) got bought out at $2.8bil by $MRK for their anti-ROR1 ADC Dec 2020; Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for $1.5 billion to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline.
  • 16
  • 1